Immune Checkpoint Inhibitor Combos Ranked for Liver Cancer in Major Analysis

A sweeping new analysis of clinical trial data has delivered one of the clearest answers yet to a question that has divided liver cancer specialists for years: which combination of immunotherapy drugs works best for patients with hepatocellular carcinoma, the most common form of liver cancer? The study, published in the journal Cancer Immunology, Immunotherapy, pooled results from eight randomized controlled trials involving 4,637 patients and used a statistical technique known as network meta-analysis to compare treatment regimens that have never been tested head-to-head in a single trial. Its conclusion is striking: pairing an immune checkpoint inhibitor with an anti-VEGF agent, a drug that blocks the tumor’s blood supply, produced better overall and progression-free survival than pairing the same class of immunotherapy with a tyrosine kinase inhibitor.

Hepatocellular carcinoma remains one of the most lethal and rapidly increasing malignancies worldwide, and its management has long been complicated by the fact that most patients are diagnosed at an advanced stage when curative options such as surgical resection or transplantation are no longer feasible. For more than a decade, the backbone of systemic treatment was tyrosine kinase inhibitors, or TKIs, oral drugs such as sorafenib and lenvatinib that interfere with the signaling pathways driving tumor growth and angiogenesis. These agents extended survival modestly but came with substantial toxicity and rarely produced meaningful tumor shrinkage. The arrival of immune checkpoint inhibitors, antibodies that release the molecular brakes that tumors place on T cells, transformed the therapeutic landscape, and combination regimens built around them have since demonstrated improved clinical outcomes in pivotal trials.

What has been missing, however, is a rigorous quantitative comparison among the different ICI-based combinations themselves. Regulators and clinicians have had to choose between dual immunotherapy, in which two checkpoint inhibitors are given together, immunotherapy plus an anti-VEGF agent, and immunotherapy plus a TKI, without direct evidence ranking one against another. The research team, led by Yishan Peng, Qiwei Yang, and Lin Yu of the Second Clinical College of Guangzhou University of Chinese Medicine, together with colleagues at several Chinese cancer centers, set out to close that gap. They systematically searched PubMed, the Cochrane Library, and Web of Science for randomized controlled trials comparing ICI-based combination systemic therapies against TKI monotherapy in patients with hepatocellular carcinoma.

The methodological core of the study is the network meta-analysis, an approach that allows simultaneous comparison of multiple interventions even when some have never been directly compared in the same trial. By placing all treatments within a single connected network of evidence, anchored by the common comparator of TKI monotherapy, the technique can estimate relative effects between any pair of regimens with quantified uncertainty. The researchers employed a random-effects model, which accounts for heterogeneity between trials, and evaluated five key outcomes: overall survival, progression-free survival, disease control rate, objective response rate, and the incidence of grade 3 or higher adverse events, the severe toxicities that most often force treatment discontinuation. They then graded the certainty of the evidence using the GRADE framework, the international standard for assessing how much confidence can be placed in medical evidence.

The headline findings are unambiguous at the level of the class. Compared with the control group receiving TKI monotherapy, ICI-based combination therapy was associated with a 25 percent reduction in the risk of death, reflected in a hazard ratio of 0.75 with a 95 percent confidence interval of 0.67 to 0.84, rated as moderate certainty evidence. Progression-free survival showed an even larger benefit, with a hazard ratio of 0.71, meaning the risk of tumor progression or death was cut by roughly 29 percent. The objective response rate, the proportion of patients whose tumors shrank measurably, was nearly four times higher with combination therapy, with an odds ratio of 3.91. These are clinically meaningful magnitudes in a disease where historical monotherapy options produced response rates in the single digits.

When the analysis turned to ranking the individual regimens, the results sharpened considerably. Immunotherapy combined with an anti-VEGF agent demonstrated superior overall survival, with a hazard ratio of 0.74, and superior progression-free survival, with a hazard ratio of 0.75, when compared directly against immunotherapy plus a TKI. The biological rationale is compelling: VEGF blockade does more than starve tumors of blood supply. It also normalizes the tumor vasculature, allowing immune cells to infiltrate the tumor microenvironment more effectively, and reduces the immunosuppressive signaling that VEGF itself promotes. In this view, the anti-VEGF agent acts as a partner to immunotherapy rather than merely a cytotoxic addition, which may explain why the pairing outperformed combinations in which the TKI, a more broadly cytostatic agent, occupies that second slot.

Not every comparison produced a decisive winner. Dual immunotherapy and immunotherapy plus anti-VEGF both significantly improved objective response rates compared with control, yet the difference between these two regimens was not statistically significant, with an odds ratio of 0.79 and a confidence interval spanning 0.42 to 1.48. Similarly, no statistically significant differences in overall or progression-free survival were observed between dual ICI therapy and ICI plus TKI combinations. On the safety front, all regimens significantly improved the objective response rate, but no regimen achieved a statistically significant advantage in disease control rate over single-agent TKIs, a nuance that reflects the different ways these endpoints capture clinical benefit. Response rate measures tumor shrinkage, while disease control also counts patients with stable disease, a category in which TKIs have historically performed respectably.

Perhaps the most clinically consequential finding emerged from the subgroup analyses. The survival benefit of ICI-based combination therapy was consistent across most predefined patient subgroups, but it disappeared among patients with hepatitis C virus infection and among those with non-viral underlying liver disease. The authors note that ICI plus TKI regimens failed to show a statistically significant overall survival benefit in any predefined subgroup, further underscoring the advantage of the anti-VEGF pairing. Because hepatocellular carcinoma almost always arises on a background of chronic liver inflammation, the etiology of that inflammation, whether hepatitis B, hepatitis C, alcohol, or metabolic dysfunction, may fundamentally shape how the immune system responds to checkpoint release. Hepatitis B-associated tumors, which dominate the trial populations included in this analysis, appear to be particularly susceptible to immunotherapy, whereas the immune microenvironment in HCV-associated and non-viral disease may respond differently.

The authors conclude that for patients with hepatocellular carcinoma, ICI-based combination systemic therapy should be considered a preferred strategy over TKI monotherapy to enhance treatment efficacy, with the notable exception of patients with HCV infection or non-viral etiology, where the evidence is less convincing. Among the evaluated regimens, the combination of an immune checkpoint inhibitor with an anti-VEGF agent stands out as the option associated with the strongest survival and progression outcomes. The team cautions, however, that further large-scale, high-quality randomized trials are warranted to validate these findings and refine patient stratification, since network meta-analysis, however sophisticated, remains an indirect form of evidence that depends on the comparability of the trials feeding the network.

For oncologists treating advanced liver cancer, the analysis offers a practical hierarchy of evidence in a field that has accumulated trials faster than it has accumulated clarity. For patients, it suggests that the choice of combination partner matters, and that the growing epidemic of metabolic liver disease, driven by rising rates of fatty liver disease and its inflammatory form, may demand dedicated trials in populations that current evidence does not yet serve well. As immunotherapy combinations continue to displace TKI monotherapy as the standard of care, studies of this kind, which rank options rather than simply confirm that a class works, are becoming the most valuable currency in precision oncology.

Subject of Research: Comparative efficacy and safety of immune checkpoint inhibitor combination therapies for hepatocellular carcinoma

Article Title: The efficacy and safety of immune checkpoint inhibitor combinations for hepatocellular carcinoma: a systematic review and network meta-analysis

Article References: The efficacy and safety of immune checkpoint inhibitor combinations for hepatocellular carcinoma: a systematic review and network meta-analysis. (n.d.). https://doi.org/10.1007/s00262-026-04548-z

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04548-z

Keywords: hepatocellular carcinoma, immune checkpoint inhibitors, network meta-analysis, anti-VEGF therapy, tyrosine kinase inhibitors, liver cancer, immunotherapy, overall survival, progression-free survival, randomized controlled trials, GRADE framework, combination therapy